IN8bio, Inc. (INAB)
| Market Cap | 310.89M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.23M |
| Shares Out | 19.43M |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | n/a |
| Last Price | n/a |
| Previous Close | n/a |
| Change ($) | n/a |
| Change (%) | n/a |
| Day's Open | n/a |
| Day's Range | n/a |
| Day's Volume | n/a |
| 52-Week Range | n/a |
News
IN8bio was founded to advance a pipeline of treatment options for glioblastoma [GBM] and acute leukemia using 'allogeneic, autologous and genetically modified gamma-delta T cells.
IN8bio, a Phase 1 biotech developing allogeneic T cell therapies for cancer and solid tumors, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
IN8bio, Inc. has filed to go public with an IPO on the New York Stock Exchange (NYSE).
About INAB
IN8bio is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. Gamma-delta T cells are naturally occurring cells in the human immune system that recognize and kill cancerous cells, while possessing a tumor recognition mechanism that protects healthy tissue. Gamma-delta T cells embody properties of both the innate and adaptive immune systems, which allows for them to serve as a funct... [Read more...]
| Industry Biotechnology | IPO Date Postponed |
| CEO William Ho | Employees 7 |
| Stock Exchange NYSE | Ticker Symbol INAB |